Table 1. Snapshot of the cell viability of HCC827 parental and mesenchymal cell lines showing IC50 values following 72h exposure to drug.
Ratio reflects the IC50 of mesenchymal/parental cells.
| Cell line: HCC827 | ||||
|---|---|---|---|---|
| Drug | Target | PAR IC50 (μM) | MES IC50 (μM) | Ratio |
| Erlotinib | EGFR inhibitor | 0.006 | >10 | >1666.667 |
| Gefitinib | EGFR inhibitor | 0.003 | >2 | 666.667 |
| Docetaxel | Chemotherapeutic agent | 0.032 | >10 | 312.500 |
| PD325901 | MEK inhibitor | 0.452 | >10 | 22.124 |
| BEZ235 | PI3K inhibitor | 0.560 | >10 | 17.857 |
| Doxorubicin | Chemotherapeutic agent | 0.009 | 0.039 | 4.427 |
| Sunitinib | VEGF inhibitor | >10 | 5.650 | 0.565 |
| BX912 | PDK1 inhibitor | 2.160 | 0.966 | 0.447 |
| PF-03814735 | Aurora kinase inhibitor | 3.569 | 1.235 | 0.346 |
| BAY 11-7821 | NF-κB inhibitor | 5.201 | 1.516 | 0.291 |
| PHA-739358 | Aurora kinase inhibitor | 3.382 | 0.759 | 0.224 |
| Dasatinib | Abl/Src inhibitor | 0.062 | 0.009 | 0.145 |